Galen buying Pfizer women’s health brands
Executive Summary
Galen enters $359 mil. agreement with Pfizer to buy hormone replacement therapy FemHRT and oral contraceptives Estrostep and Loestrin. Galen could pay as much as an additional $125 mil. if products retain market exclusivity over course of patent life. Pfizer announced in January that it was seeking a buyer for the women's health line (1"The Pink Sheet" Jan. 27, p. 21). Galen's women's health line was recently expanded with purchase of Lilly's pre-menstrual dysphoric disorder therapy Sarafem (2"The Pink Sheet" Dec. 16, 2002, p. 34). Galen was an obvious bidder for the Pfizer brands: CEO Roger Boissonneault is a named inventor on three Estrostep and FemHRT product patents and on patent for credit card-style packaging for Loestrin and Estrostep, Galen says...
You may also be interested in...
Galen brings oral contraceptive manufacturing in house
Galen will transfer manufacturing of its oral contraceptive Ovcon from Bristol-Myers Squibb to its newly-acquired plant in Fajardo, Puerto Rico. The company purchased the plant from Pfizer. The OC Estrostep, which Galen acquired from Pfizer in 2003, is one product currently manufactured at the site (1"The Pink Sheet" March 10, 2003, In Brief). Galen plans to move other products from contract manufacturers to Fajardo. The company will continue to manufacture the Pfizer drugs produced at the facility until they are transferred...
Galen Settles Estrostep, FemHRT Litigation, Barr Picks Up Loestrin In Deal
A product licensing agreement between Galen and Barr will settle FemHRT and Estrostep patent litigation inherited by Galen from Pfizer
Pfizer’s Women’s Health Initiative: Divest FemHRT And Contraceptive Line
Pfizer plans to divest its hormone replacement therapy FemHRT during the first half of 2003